Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction In Vitro and In Vivo

Journal of Virology

Volumn 87, Issue 8, 2013, Pages 4571-4583

  Mitchell, Angela M ^a   Li, Chengwen ^a   Samulskia, R Jude ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; PARVOVIRUS VECTOR; PROTEASOME; REACTIVE OXYGEN METABOLITE;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL MIGRATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE DOSAGE; GENE EXPRESSION; HELPER VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERINUCLEAR REGION; PRIORITY JOURNAL; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS CAPSID; VIRUS GENOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL LINE; DEPENDOVIRUS; HUMANS; OXIDES; TRANSDUCTION, GENETIC; VIRION; VIRUS REPLICATION;

ADENO-ASSOCIATED VIRUS; MIRIDAE;

EID: 84875766008     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03443-12     Document Type: Article

References (61)

1. Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA. 2001. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J. Virol. 75:6969-6976.
2. Xiao X, Xiao W, Li J, Samulski RJ. 1997. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J. Virol. 71:941-948.
3. Mitchell AM, Nicolson SC, Warischalk JK, Samulski RJ. 2010. AAV's anatomy: roadmap for optimizing vectors for translational success. Curr. Gene Ther. 10:319-340.
4. Bartlett JS, Wilcher R, Samulski RJ. 2000. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74: 2777-2785.
5. Xiao PJ, Samulski RJ. 2012. Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network. J. Virol. 86:10462-10473.
6. Johnson JS, Samulski RJ. 2009. Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J. Virol. 83:2632-2644.
7. Xiao W, Warrington KH, Jr, Hearing P, Hughes J, Muzyczka N. 2002. Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2. J. Virol. 76:11505-11517.
8. Ferrari FK, Samulski T, Shenk T, Samulski RJ. 1996. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70:3227-3234.
9. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. 2003. Adeno-associated virus terminal repeat (TR) mutant generates selfcomplementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 10:2112-2118.
10. Johnson JS, Gentzsch M, Zhang L, Ribeiro CM, Kantor B, Kafri T, Pickles RJ, Samulski RJ. 2011. AAV exploits subcellular stress associated with inflammation, endoplasmic reticulum expansion, and misfolded proteins in models of cystic fibrosis. PLoS Pathog. 7:e1002053. doi:10 .1371/journal.ppat.1002053.
11. Zhong L, Qing K, Si Y, Chen L, Tan M, Srivastava A. 2004. Heat-shock treatment-mediated increase in transduction by recombinant adenoassociated virus 2 vectors is independent of the cellular heat-shock protein 90. J. Biol. Chem. 279:12714-12723.
12. Yalkinoglu AO, Heilbronn R, Burkle A, Schlehofer JR, Hausen H. 1988. DNA amplification of adeno-associated virus as a response to cellular genotoxic stress. Cancer Res. 48:3123-3129.
13. Golding I. 2011. Decision making in living cells: lessons from a simple system. Annu. Rev. Biophys. 40:63-80.
14. van der Ven A, van Diest R, Hamulyak K, Maes M, Bruggeman C, Appels A. 2003. Herpes viruses, cytokines, and altered hemostasis in vital exhaustion. Psychosom. Med. 65:194-200.
15. Huang W, Xie P, Xu M, Li P, Zao G. 2011. The influence of stress factors on the reactivation of latent herpes simplex virus type 1 in infected mice. Cell Biochem. Biophys. 61:115-122.
16. Douar AM, Poulard K, Stockholm D, Danos O. 2001. Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J. Virol. 75:1824-1833.
17. Monahan PE, Lothrop CD, Sun J, Hirsch ML, Kafri T, Kantor B, Sarkar R, Tillson DM, Elia JR, Samulski RJ. 2010. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol. Ther. 18:1907-1916.
18. Russell DW, Alexander IE, Miller AD. 1995. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc. Natl. Acad. Sci. U. S. A. 92:5719-5723.
19. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. 2000. Endosomal processing limits gene transfer to polarized airway epithelia by adenoassociated virus. J. Clin. Investig. 105:1573-1587.
20. Ju XD, Lou SQ, Wang WG, Peng JQ, Tian H. 2004. Effect of hydroxyurea and etoposide on transduction of human bone marrow mesenchymal stem and progenitor cell by adeno-associated virus vectors. Acta Pharmacol. Sin. 25:196-202.
21. Prasad KM, Xu Y, Yang Z, Toufektsian MC, Berr SS, French BA. 2007. Topoisomerase inhibition accelerates gene expression after adenoassociated virus-mediated gene transfer to the mammalian heart. Mol. Ther. 15:764-771.
22. Cornelis T, Beckers EA, Driessen AL, van der Sande FM, Koek GH. 2012. Bortezomib-associated fatal liver failure in a haemodialysis patient with multiple myeloma. Clin. Toxicol. 50:444-445.
23. Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY, Lau JS, Kwong YL. 2011. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood 118:6535-6543.
24. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, Kim BK, Lee YY. 2000. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclindependent kinase inhibitor, p21, and apoptosis. Cancer Res. 60:3065-3071.
25. List A, Beran M, DiPersio J, Slack J, Vey N, Rosenfeld CS, Greenberg P. 2003. Opportunities for trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 17:1499-1507.
26. Baljevic M, Park JH, Stein E, Douer D, Altman JK, Tallman MS. 2011. Curing all patients with acute promyelocytic leukemia: are we there yet? Hematol. Oncol. Clin. North Am. 25:1215-1233.
27. Spuches AM, Kruszyna HG, Rich AM, Wilcox DE. 2005. Thermodynamics of the As(III)-thiol interaction: arsenite and monomethylarsenite complexes with glutathione, dihydrolipoic acid, and other thiol ligands. Inorg. Chem. 44:2964-2972.
28. Dai J, Weinberg RS, Waxman S, Jing Y. 1999. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93:268-277.
29. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY, Karin M. 2000. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J. Biol. Chem. 275:36062-36066.
30. 3. Cancer Cell 18:88-98.
31. Larochette N, Decaudin D, Jacotot E, Brenner C, Marzo I, Susin SA, Zamzami N, Xie Z, Reed J, Kroemer G. 1999. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp. Cell Res. 249:413-421.
32. Hong SH, Yang Z, Privalsky ML. 2001. Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia. Mol. Cell. Biol. 21: 7172-7182.
33. Park JW, Choi YJ, Jang MA, Baek SH, Lim JH, Passaniti T, Kwon TK. 2001. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem. Biophys. Res. Commun. 286:726-734.
34. Malbec M, Pham QT, Plourde MB, Letourneau-Hogan A, Nepveu- Traversy ME, Berthoux L. 2010. Murine double minute 2 as a modulator of retroviral restrictions mediated by TRIM5alpha. Virology 405:414-423.
35. Sebastian S, Sokolskaja E, Luban J. 2006. Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologues in a cell type-dependent manner. J. Virol. 80:2051-2054.
36. Stalder R, Blanchet F, Mangeat B, Piguet V. 2010. Arsenic modulates APOBEC3G-mediated restriction to HIV-1 infection in myeloid dendritic cells. J. Leukoc. Biol. 88:1251-1258.
37. Au WY, Kwong YL. 2005. Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge. J. Am. Acad. Dermatol. 53:890-892.
38. Nouri K, Ricotti CA, Jr, Bouzari N, Chen H, Ahn E, Bach A. 2006. The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide. J. Drugs Dermatol. 5:182-185.
39. Jennings K, Miyamae T, Traister R, Marinov A, Katakura S, Sowders D, Trapnell B, Wilson JM, Gao G, Hirsch R. 2005. Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo. Mol. Ther. 11:600-607.
40. Grieger JC, Choi VW, Samulski RJ. 2006. Production and characterization of adeno-associated viral vectors. Nat. Protoc. 1:1412-1428.
41. Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, Takeshita K, Takeshita A, Ohno R. 1998. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 12:1383-1391.
42. Xiao PJ, Li C, Neumann A, Samulski RJ. 2012. Quantitative 3D tracing of gene-delivery viral vectors in human cells and animal tissues. Mol. Ther. 20:317-328.
43. Gu Y, Lewis DF, Zhang Y, Groome LJ, Wang Y. 2006. Increased superoxide generation and decreased stress protein Hsp90 expression in human umbilical cord vein endothelial cells (HUVECs) from pregnancies complicated by preeclampsia. Hypertens. Pregnancy 25:169-182.
44. Li C, Diprimio N, Bowles DE, Hirsch ML, Monahan PE, Asokan A, Rabinowitz J, Agbandje-McKenna M, Samulski RJ. 2012. Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J. Virol. 86:7752-7759.
45. Sanlioglu S, Benson PK, Yang J, Atkinson EM, Reynolds T, Engelhardt JF. 2000. Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J. Virol. 74:9184-9196.
46. Miller WH, Jr, Schipper HM, Lee JS, Singer J, Waxman S. 2002. Mechanisms of action of arsenic trioxide. Cancer Res. 62:3893-3903.
47. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, Bishop JM, de The H. 1999. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 189:1043-1052.
48. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360.
49. Keiser NW, Yan Z, Zhang Y, Lei-Butters DC, Engelhardt JF. 2011. Unique characteristics of AAV1, 2, and 5 viral entry, intracellular trafficking, and nuclear import define transduction efficiency in HeLa cells. Hum. Gene Ther. 22:1433-1444.
50. Liu Y, Joo KI, Wang P. 2012. Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells. Gene Ther. doi:10.1038 /gt.2012.41. [Epub ahead of print.]
51. Sanlioglu S, Engelhardt JF. 1999. Cellular redox state alters recombinant adeno-associated virus transduction through tyrosine phosphatase pathways. Gene Ther. 6:1427-1437.
52. Wheeler MD, Kono H, Rusyn I, Arteel GE, McCarty D, Samulski RJ, Thurman RG. 2000. Chronic ethanol increases adeno-associated viral transgene expression in rat liver via oxidant and NFkappaB-dependent mechanisms. Hepatology 32:1050-1059.
53. Jayandharan GR, Aslanidi G, Martino AT, Jahn SC, Perrin GQ, Herzog RW, Srivastava A. 2011. Activation of the NF-kappaB pathway by adenoassociated virus (AAV) vectors and its implications in immune response and gene therapy. Proc. Natl. Acad. Sci. U. S. A. 108:3743-3748.
54. Geoffroy MC, Chelbi-Alix MK. 2011. Role of promyelocytic leukemia protein in host antiviral defense. J. Interferon Cytokine Res. 31:145-158.
55. Hwang DR, Tsai YC, Lee JC, Huang KK, Lin RK, Ho CH, Chiou JM, Lin YT, Hsu JT, Yeh CT. 2004. Inhibition of hepatitis C virus replication by arsenic trioxide. Antimicrob. Agents Chemother. 48:2876-2882.
56. Kuroki M, Ariumi Y, Ikeda M, Dansako H, Wakita T, Kato N. 2009. Arsenic trioxide inhibits hepatitis C virus RNA replication through modulation of the glutathione redox system and oxidative stress. J. Virol. 83: 2338-2348.
57. Bulliard Y, Narvaiza I, Bertero A, Peddi S, Rohrig UF, Ortiz M, Zoete V, Castro-Diaz N, Turelli P, Telenti A, Michielin O, Weitzman MD, Trono D. 2011. Structure-function analyses point to a polynucleotideaccommodating groove essential for APOBEC3A restriction activities. J. Virol. 85:1765-1776.
58. Geelen JL, Boom R, Klaver GP, Minnaar RP, Feltkamp MC, van Milligen FJ, Sol CJ, van der Noordaa J. 1987. Transcriptional activation of the major immediate early transcription unit of human cytomegalovirus by heat-shock, arsenite and protein synthesis inhibitors. J. Gen. Virol. 68(Pt 11):2925-2931.
59. Sides MD, Block GJ, Shan B, Esteves KC, Lin Z, Flemington EK, Lasky JA. 2011. Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells. Virology 416:86-97.
60. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA. 2006. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med. 12:342-347.
61. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, o'beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM. 2011. Adenovirus-associated virus vectormediated gene transfer in hemophilia B. N. Engl. J. Med. 365:2357-2365.